

Resource Summary Report

Generated by [dkNET](#) on Aug 28, 2026

BD Biosciences: FACSCanto Flow Cytometer

RRID:SCR_018055

Type: Tool

Proper Citation

BD Biosciences: FACSCanto Flow Cytometer (RRID:SCR_018055)

Resource Information

URL: <https://www.bdbiosciences.com/en-us/instruments/clinical-instruments/clinical-cell-analyzers/facscanto>

Proper Citation: BD Biosciences: FACSCanto Flow Cytometer (RRID:SCR_018055)

Description: Flow cytometry system that performs reliable performance, accuracy, and ease-of-use for clinical diagnostic services. System has 10 color capability, optical enhancements, and 4-3-3 configuration deliver high sensitivity and resolution for accurate results.

Synonyms: Canto-blue and red lasers

Resource Type: instrument resource

Keywords: ABRF, Flow Cytometer, flow cytometry, multicolor analysis, BD FACSCanto, instrument, equipment

Resource Name: BD Biosciences: FACSCanto Flow Cytometer

Resource ID: SCR_018055

Alternate IDs: Model_Number_Canto

Alternate URLs: https://www.bdbiosciences.com/content/dam/bdb/marketing-documents/facscanto_techsspecs.pdf

Record Creation Time: 20220129T080338+0000

Record Last Update: 20260815T182546+0000

Ratings and Alerts

No rating or validation information has been found for BD Biosciences: FACSCanto Flow Cytometer.

No alerts have been found for BD Biosciences: FACSCanto Flow Cytometer.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 22 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Kim SH, et al. (2026) Association of Macrophage Accumulation and Polarization in Patients with Obesity and Diabetes with Diabetic Remission After Bariatric Surgery. Obesity surgery, 36(2), 404.

Wu N, et al. (2026) Arginine deprivation enhances ASS1-negative glioblastoma radiosensitivity via epigenetic silencing of DNA repair genes. Cell death & disease.

Tran B, et al. (2026) Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(14), 2850.

Brevi A, et al. (2026) Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression. Cancer research, 86(12), 2860.

Carneiro BA, et al. (2025) Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors. Cancer research communications, 5(3), 444.

Juric D, et al. (2025) A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies. Cancer research communications, 5(11), 2025.

Maligireddy SS, et al. (2025) Targeting a pathogenic cryptic exon that drives HLRCC to induce exon skipping. Molecular therapy. Nucleic acids, 36(3), 102668.

Giusti V, et al. (2025) Establishment and Characterization of OS-MET-R-092: A Novel Patient-Derived Cell Culture from an Osteosarcoma Bone Metastasis. International journal of molecular sciences, 26(21).

Krüger C, et al. (2025) Epidermal growth factor receptor specific immunotherapy for SHH medulloblastoma tested in an in vitro blood-brain barrier-model. Cancer treatment and research communications, 44, 100950.

Fieni C, et al. (2024) Prevention of prostate cancer metastasis by a CRISPR-delivering nanoplatfrom for interleukin-30 genome editing. *Molecular therapy : the journal of the American Society of Gene Therapy*, 32(11), 3932.

Thomas JR, et al. (2024) Abcg2a is the functional homolog of human ABCG2 expressed at the zebrafish blood-brain barrier. *Fluids and barriers of the CNS*, 21(1), 27.

Yada Y, et al. (2024) STIM-mediated calcium influx regulates maintenance and selection of germinal center B cells. *The Journal of experimental medicine*, 221(1).

Boutin L, et al. (2024) Camelid-derived Tcell engagers harnessing human ?? T cells as promising antitumor immunotherapeutic agents. *European journal of immunology*, 54(8), e2350773.

Robey RW, et al. (2024) The Methyltransferases METTL7A and METTL7B Confer Resistance to Thiol-Based Histone Deacetylase Inhibitors. *Molecular cancer therapeutics*, 23(4), 464.

Fu Y, et al. (2023) A synthetic notch (synNotch) system linking intratumoral immune-cancer cell communication to a synthetic blood biomarker assay. *Frontiers in pharmacology*, 14, 1304194.

Chambers C, et al. (2023) SWI/SNF Blockade Disrupts PU.1-Directed Enhancer Programs in Normal Hematopoietic Cells and Acute Myeloid Leukemia. *Cancer research*, 83(7), 983.

Girone C, et al. (2023) The RIG-I agonist M8 triggers cell death and natural killer cell activation in human papillomavirus-associated cancer and potentiates cisplatin cytotoxicity. *Cancer immunology, immunotherapy : CII*, 72(9), 3097.

Lozano-Rabella M, et al. (2023) Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(12), 2250.

Hurtado-Navarro L, et al. (2023) NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy. *Cell reports. Medicine*, 4(12), 101329.

Cevallos C, et al. (2022) HIV-induced bystander cell death in astrocytes requires cell-to-cell viral transmission. *Journal of neurochemistry*, 163(4), 338.